12:00 AM
 | 
Feb 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral interferon-alpha lozenges: Additional Phase II data

A post-hoc subgroup analysis of subjects 55 years of age and older (n=64) vaccinated with the Fluvax influenza vaccine prior to enrolling in a double-blind, Australian Phase II trial showed that the incidence of influenza-like illness was significantly lower for subjects receiving once-daily oral interferon-alpha lozenges for 16 weeks vs. placebo...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >